NAPLEX Question of the Day
Test your knowledge with a hand-picked multiple-choice question.
A 34-year-old woman with recurrent vulvovaginal candidiasis due to non-albicans species has failed multiple azole therapies and cannot tolerate systemic agents because of drug interactions. She is not pregnant and seeks a local, non-oral option recommended by her gynecologist. She prefers a bedtime product with minimal mess and acceptable for 14 days of therapy. She requests a compounded preparation since no commercial product is available to meet the recommendation. The pharmacist must provide an appropriate nonsterile compounded dosage form that targets the vagina, avoids systemic exposure, and uses an ingredient that should never be taken by mouth. Which formulation best meets these needs and safety considerations?
Which of the following formulations is most appropriate for this patient?